

Detailed Table of Contents

	<i>Main Volume</i>	<i>Supple- ment</i>
Foreword.....	vii	vii
Preface to the Third Edition.....	ix	ix
Preface to the Second Edition.....	xiii	—
Preface to the First Edition.....	xvii	—
Acknowledgments.....	—	—
About the Authors.....	xxv	xi
Summary Table of Contents.....	xxxv	xxiii
Chapter 1 An Introduction to Health Care Fraud and Abuse.....	1	1-1
I. Introduction.....	2	1-3
A. The Potential Risks Throughout the Health Care Industry [Substitute Text].....	—	1-3
1. Notable Cases and Settlements [Substitute Text].....	—	1-9
2. Notable Defense Victories.....	24	1-41
B. Exposure for Attorneys.....	26	1-51
C. Likelihood of Increased Enforcement Efforts in the Future.....	32	1-52
1. Pharmaceuticals and Medical Devices [Revised Topic, Substitute Text].....	—	1-55
2. Hospitals/Health Systems [Substitute Text].....	38	1-63
3. Other Providers/Suppliers.....	40	1-67
4. Medicare Part D.....	40	—
5. State Enforcement [Substitute Text].....	—	1-68
6. Private Enforcement [Substitute Text].....	—	1-74
7. RACs, MEDICs, ZPICs, and UPICs [Revised Topic, Substitute Text].....	—	1-78
8. Disclosure of Physician Relationships With Drug and Device Vendors [Substitute Text].....	—	1-84
9. Electronic Health Records [New Topic].....	—	1-86
10. Health Insurance Marketplaces [New Topic].....	—	1-90
11. Health Care Executive Liability [New Topic].....	—	1-92
12. Private Equity Companies [New Topic].....	—	1-97

	<i>Main Volume</i>	<i>Supple- ment</i>
II. The Federal Fraud and Abuse Laws.....	51	1-98
A. The Anti-Kickback Statute	52	1-98
1. The Prohibitions	52	1-98
2. Exceptions and Safe Harbors.....	53	1-98
3. Special Fraud Alerts and Special Advisory Bulletins.....	56	1-99
4. Office of Inspector General Advisory Opinions [Substitute Text].....	—	1-103
5. Other Guidance.....	62	1-108
6. Enforcement	64	1-112
B. The Stark Law.....	66	1-113
1. The Prohibitions	66	1-113
2. The Exceptions	69	1-114
3. Available Guidance: Preambles, Advisory Opinions, and Court Decisions [Substitute Text]	—	1-116
4. Specialty Hospitals	74	1-120
5. Enforcement [Substitute Text].....	—	1-123
C. False Claims Statutes.....	82	1-133
1. The False Claims Act.....	82	1-133
2. The 60-Day Overpayment Rule [New Topic].....	—	1-145
3. Other Statutes Prohibiting False Claims [Renumbered Topic, Formerly II.C.2.].....	88	1-148
D. Civil Monetary Penalties	89	1-148
1. The Prohibitions	89	1-149
2. Beneficiary Inducement.....	93	1-149
3. Gainsharing [Substitute Text].....	—	1-150
4. Drug Product and Price Reporting	99	—
5. CMP Enforcement.....	99	1-151
E. Exclusion Authorities.....	100	1-153
1. Mandatory Exclusion.....	100	—
2. Permissive Exclusion.....	101	1-154
3. Special Advisory Bulletin on Exclusion.....	103	1-155
4. Exclusion of Corporate Officers	105	—
F. Federal All-Payor Statutes	106	—
G. Screening Procedures for Providers and Suppliers	107	1-155
III. State Laws	108	1-156
IV. Other Resources	112	1-158
A. Compliance Program Guidance.....	113	1-159
B. The OIG Work Plans [Substitute Text].....	—	1-161
C. The OIG Semiannual Reports [Substitute Text].....	—	1-168
D. Enforcement Resources	118	1-169
1. The OIG’s Provider Self-Disclosure Protocol.....	118	—
2. The Inspector General’s Open Letter on the CIA Process.....	120	—
3. The CMS Self-Referral (Stark Law) Disclosure Protocol [Substitute Text].....	—	1-169
E. Other Guidance.....	122	1-172
F. Miscellaneous	124	—
V. Conclusion	125	—

	<i>Main Volume</i>	<i>Supple- ment</i>
Chapter 2 Federal Physician Self-Referral Restrictions	127	2-1
I. Introduction.....	131	—
II. Historical Background	132	2-6
A. Legislative History.....	132	—
B. Regulatory History.....	133	2-6
1. Sanctions.....	133	—
2. Stark I	134	—
3. Stark II Proposed Rule.....	134	—
4. Stark II Final Rules.....	134	—
a. Phases I and II	134	—
b. Phase III Final Rule.....	135	—
c. CMS’s Approach to Drafting the Final Rules.....	135	—
5. EHR Donation Final Rule	136	—
6. Annual Rulemaking Cycle [Substitute Text].....	136	2-6
C. Affordable Care Act (ACA).....	136	2-6
D. Effective Dates.....	137	2-7
E. Interaction With State Self-Referral Laws	139	—
III. General Prohibition and Key Statutory Terms	139	2-8
A. The General Prohibition	139	—
B. Key Statutory Terms	140	2-8
1. Referral.....	140	2-8
2. Entity	142	—
a. Revised Definition of “Entity”	142	—
b. Performing a DHS.....	143	—
3. Financial Relationship.....	144	—
4. Ownership or Investment Interest.....	144	—
a. Direct Ownership or Investment Interest.....	144	—
b. Indirect Ownership or Investment Interest.....	145	—
5. Compensation Arrangement	146	—
6. Remuneration	147	2-8
7. Knowledge Standard.....	148	—
C. Temporary Noncompliance Exception	149	—
D. Alternative Method of Compliance With Signature Requirement [Substitute Text].....	150	2-9
IV. Designated Health Services	151	—
A. Listed Designated Health Services	151	—
B. General Principles.....	151	—
C. Radiology and Certain Other Imaging Services	152	—
D. Outpatient Prescription Drugs	152	—
E. Inpatient and Outpatient Hospital Services	153	—
V. Exceptions Related to Physician Compensation.....	153	2-10
A. Introduction.....	153	—
B. Volume or Value, Other Business Generated, and Set in Advance	154	2-10
1. Volume or Value of Referrals.....	154	2-11
a. Payments to Comply With Utilization Protocols, Reduce Costs, and Decrease Rate of Readmission [New Topic].....	—	2-11

	<i>Main Volume</i>	<i>Supple- ment</i>
2. Other Business Generated	157	—
3. Set-in-Advance Test.....	158	—
a. Percentage-Based Compensation and Productivity Bonuses.....	158	—
b. Specific Formula	159	—
C. Fair Market Value Definition	160	2-12
D. Commercially Reasonable	163	—
E. Directed Referrals	163	—
F. Compensation to Physician Employees.....	163	2-15
1. The Bona Fide Employment Exception [Substitute Text].....	163	2-15
2. Leased Employees.....	164	—
G. Compensation to Physician Independent Contractors and Physicians in the Group	164	—
VI. Indirect Compensation Definition and Exception.....	164	2-18
A. Definitions	165	—
1. Unbroken Chain Test.....	165	—
2. Volume or Value or Other Business Generated Test.....	165	—
3. Knowledge.....	166	—
B. Exception for Indirect Compensation Arrangements	166	2-18
C. The Physician “Stand in the Shoes” Rule.....	167	—
D. Physician Organization.....	171	—
E. The Grandfathering Provision	171	—
F. DHS Entity “Stand in the Shoes”	172	—
VII. Definition of Group Practice and Exceptions for In-Office Ancillary Services and Physician Services	173	2-18
A. Group Practice Definition.....	173	2-18
1. Single Legal Entity.....	174	—
2. Members of the Group.....	175	—
3. Physician in the Group Practice.....	175	—
4. The “Full Range of Services” Test	176	—
5. The “Substantially All” Test	176	—
6. The Unified Business Test.....	178	—
7. Compensation: Profit Shares and Productivity Bonuses.....	179	—
8. Group Practice Productivity Bonuses Related to “Incident to” Services and Supplies	180	—
9. Foundation-Model Group Practices.....	181	—
B. In-Office Ancillary Services Exception.....	182	2-19
1. Scope of DHS That Can Be In-Office Ancillary Services.....	182	—
2. Building Requirements.....	183	2-19
a. Centralized Building	183	—
b. Same Building	183	2-19
i. Shared Space in “Same Building”.....	186	—
3. Direct Supervision.....	186	—
4. Billing Requirements.....	187	—

	<i>Main Volume</i>	<i>Supple- ment</i>
5. Clarification of Interplay of In-Office Ancillary Services Exception and Reassignment and Purchased Diagnostic Tests	188	—
6. Disclosure Requirements for Certain Imaging Services.....	188	—
C. Exception for Physician Services	189	—
VIII. Managed Care Prepaid Plans and Risk-Sharing Exceptions....	190	—
A. The Prepaid Plan Exception.....	190	—
B. Risk-Sharing Compensation Arrangements Exception	191	—
IX. Exception for Academic Medical Centers	192	—
A. Teaching Hospital	193	—
B. Referring Physician	193	—
C. Compensation to Physicians in Academic Medical Centers	194	—
D. Faculty Practice Plans.....	195	—
E. Other AMC Exception Requirements.....	195	—
X. Other Exceptions Related to Both Ownership and Compensation	196	—
A. Implants Furnished in Ambulatory Surgery Centers	196	—
B. EPO and Other Dialysis-Related Outpatient Prescription Drugs	197	—
C. Preventive Screening Tests, Vaccinations, and Immunizations	197	—
D. Eyeglasses and Contact Lenses Following Cataract Surgery.....	198	—
E. Intra-Family Referrals in Rural Areas	198	—
XI. Ownership and Investment Interest Exceptions.....	200	2-20
A. Publicly Traded Securities and Mutual Funds	200	—
B. Specific Providers.....	201	2-20
1. Hospital Ownership in Puerto Rico.....	201	—
2. Rural Providers.....	201	—
3. Hospital Ownership.....	202	2-20
a. Specialty Hospital Moratorium	203	—
b. ACA Limitations on Physician-Owned Hospitals.....	204	—
i. Basic Restrictions.....	204	—
ii. Expansion of Physician-Owned Hospitals.....	206	—
iii. Timing Issues	207	—
c. The Whole Hospital Exception and the 2011 OPSS Final Rule.....	207	2-20
d. The Whole Hospital Exception and the 2012 OPSS Final Rule.....	209	—
e. The Whole Hospital Exception and the 2016 MPFS Final Rule [New Topic]	—	2-20
XII. Statutory Compensation Exceptions.....	210	2-21
A. Rental of Office Space and Equipment.....	211	2-21
1. Amendments.....	211	—
2. Sharing Space or Equipment	212	—

	<i>Main Volume</i>	<i>Supple- ment</i>
3. Holdover [Substitute Text].....	213	2-21
4. Early Termination	213	—
5. Subleases	213	—
6. “Per Click” or Percentage Leases	214	—
7. Capital Leases.....	214	—
B. Personal Service Arrangement Exception	214	2-22
1. Termination.....	215	—
2. Master List of Contracts	215	—
3. “Furnishing Services”.....	216	—
4. Physician Incentive Plans	216	—
5. Amendments.....	216	—
C. Physician Recruitment	217	2-23
1. Providers Subject to the Rule	217	—
2. Income Guarantees and Allocated Costs	218	—
3. Unavailability of Other Exceptions	218	—
4. Relocation Requirement	219	—
5. Geographic Area Served by the Hospital	220	—
6. Referral Considerations	220	—
7. Seeding Arrangements.....	220	—
a. Flow of Funds.....	221	—
b. Overhead Payments	222	—
c. Practice Restrictions	223	—
8. Anti-Kickback Compliance	224	—
9. Written Agreement Signed by All Parties.....	224	—
10. Other Issues	224	2-23
D. Isolated Transactions	225	—
E. Remuneration Unrelated to the Provision of Designated Health Services	226	—
F. Certain Group Practice Arrangements With Hospitals	227	—
G. Payments by a Physician for Items and Services.....	228	—
XIII. Compensation Exceptions Created by Regulation.....	229	2-23
A. Introduction [Substitute Text]	229	2-23
B. The FMV Exception (Phase I).....	229	—
C. Charitable Donations by Physicians (Phase II)	229	—
D. Nonmonetary Compensation (Phase I).....	230	—
E. Medical Staff Incidental Benefits (Phase I).....	231	—
F. Compliance Training (Phase I)	232	—
G. Referral Services and Obstetrical Malpractice Insurance Subsidies (Phase II)	233	—
H. Professional Courtesy (Phase II)	233	—
I. Retention Payments in Underserved Areas (Phase II).....	234	2-23
J. Community-Wide Health Information Systems (Phase II).....	236	—
K. Electronic Health Records Exception.....	236	—
L. Assistance to Compensate a Nonphysician Practitioner [New Topic]	—	2-24
1. Remuneration [New Topic]	—	2-24
2. Compensation Arrangement [New Topic]	—	2-24
3. Geographic Area [New Topic].....	—	2-24
4. Patient Care Services [New Topic].....	—	2-25

	<i>Main Volume</i>	<i>Supple- ment</i>
5. Limits on Repeated Use [New Topic].....	—	2-25
M. Timeshare Arrangements [New Topic].....	—	2-25
1. Relationship With the Lease Exception [New Topic].....	—	2-26
2. Licensor and Licensee [New Topic].....	—	2-26
3. Use Restrictions [New Topic].....	—	2-26
N. Writing and Signature Requirements [New Topic].....	—	2-26
XIV. Application of Stark to State Medicaid Programs	238	2-28
XV. Enforcement Against Physicians [New Topic].....	—	2-29
XVI. Reporting Requirements and Sanctions [Renumbered Topic, Formerly XV.]	239	2-30
A. Reporting Requirements	239	—
B. Sanctions.....	241	—
C. Burden of Proof	242	—
D. Period of Disallowance.....	242	—
XVII. Differences Between the Stark Law and the Federal Anti-Kickback Statute [Renumbered Topic, Formerly XVI.]	243	2-30
XVIII. Stark Voluntary Self-Disclosure Protocol [Renumbered Topic, Formerly XVII.]	245	2-30
XIX. Stark Law Advisory Opinions [Renumbered Topic, Formerly XVIII.].....	249	2-32
XX. Shared Saving Program: Fraud and Abuse Waivers [Renumbered Topic, Formerly XIX.].....	251	2-32
XXI. Fraud and Abuse Waivers for Bundled Payments and Other Programs [New Topic]	—	2-36
XXII. Conclusion [Renumbered Topic, Formerly XX.].....	254	2-36
 Chapter 3 The False Claims Act in Health Care Prosecutions: Application of the Substantive, <i>Qui Tam</i>, and Voluntary Disclosure Provisions	 255	 3-1
I. Introduction.....	258	3-4
II. Construction of the “False” and “Knowing” Elements of the False Claims Act and False Claims Act Damages	261	3-5
A. Falsity.....	262	3-6
1. Factual Falsity.....	264	—
2. Legally False Certification	264	3-6
a. Express False Certification.....	264	3-6
b. Implied False Certification [Substitute Text]	271	3-12
3. Cases in Which Courts Refused to Find That Defendant Submitted False or Fraudulent Claims or Statements	273	—
a. Literal Compliance.....	273	—
b. Nonobjective False Claims.....	274	—
B. The FCA “Knowing” Standard.....	277	3-14
1. Reckless Disregard	278	—
2. Deliberate Ignorance	280	—
3. Defenses Demonstrating Lack of Knowledge	283	3-14

	Main Volume	Supple- ment
a. Merely Negligent Conduct Does Not Result in Liability Under the FCA	285	—
b. The Government Cannot Predicate an FCA Action on Ambiguous Regulatory Guidance.....	290	—
c. Government Knowledge May Provide a Defense.....	291	—
d. The Defendants’ Reliance on Sound Legal Theory Negates an Inference of Fraud	294	3-14
C. Materiality.....	303	3-15
1. Government Awareness of the Alleged Falsity	303	3-15
2. Whether a Statement Could Have Influenced the Government’s Funding Decision	306	3-20
D. FCA Damages and Civil Penalties.....	308	3-21
1. Kickbacks and Regulatory Violations.....	308	—
2. Determination of Number of Civil Penalties	313	3-21
a. CMS-1500 Form.....	315	—
b. UB-92 Forms and Cost Reports	316	—
c. Dollar Amount of Civil Penalties Assessed Against Defendant.....	319	—
3. Constitutional Limitations on Civil Penalties.....	320	3-22
a. The Eighth Amendment	321	3-23
i. Extent and Harm of Defendant’s FCA Violations [Substitute Text].....	322	3-23
ii. Comparable Penalties [Substitute Text]	324	3-24
iii. Class for Whom the FCA Was Principally Designed.....	324	—
III. Preempting FCA Actions: The Office of Inspector General’s Voluntary Disclosure Program	324	—
A. The Voluntary Disclosure Process	324	—
B. Benefits and Risks of Submitting a Self-Disclosure.....	325	—
1. Risks of Disclosure.....	325	—
2. Incentives for Disclosure	335	—
IV. Congress’s 2009 Revisions to the False Claims Act	336	—
A. Legislative History: The 1986 Amendments to the FCA.....	337	—
B. Post-1986 Case Law	339	—
1. The Link Between Claims and Presentment: <i>Totten</i> and <i>Allison Engine</i>	339	—
a. The D.C. Circuit’s Ruling in <i>Totten</i>	339	—
b. The Supreme Court’s Decision in <i>Allison Engine</i>	340	—
2. Reverse False Claims Case Law Developments.....	342	—
3. Statute of Limitations Case Law Developments	343	—
4. Whistleblower Retaliation Case Law Developments	343	—
C. Congress’s 2009 FCA Amendments	344	—
1. The Senate’s FCA Amendments.....	344	—
a. February 5, 2009, S. 386	344	—
b. DOJ’s February 25, 2009, Letter	346	—

	<i>Main Volume</i>	<i>Supple- ment</i>
c. Senate Judiciary Committee Report (March 2009).....	350	—
d. April 22, 2009, Floor Statements	355	—
2. The House’s 2009 FCA Amendments (May 6, 2009).....	359	—
a. Revisions to the Whistleblower Retaliation Provision.....	360	—
b. Statute of Limitations Provision.....	360	—
c. State Service Provision.....	361	—
d. Civil Investigative Demands.....	361	—
3. Expansion and Contraction of the FCA Resulting From the 2009 Amendments	363	—
a. Revisions to Subsections (a)(1)–(a)(2) (False Claims and Statements) and the Definition of “Claim”.....	363	—
b. Revisions to Subsection (a)(3) (Conspiracy).....	364	—
c. Revisions to Subsection (a)(7) (Reverse False Claims)	364	—
d. Statute of Limitations	365	—
e. Whistleblower Retaliation.....	365	—
f. Projected Impact.....	365	—
V. The 2010 Amendments to the False Claims Act.....	366	3-25
A. Amendments to the Public Disclosure Bar.....	366	3-25
1. Congress’s Revisions That Appear to Embrace or Adopt Existing Precedent	368	—
a. Reference to Action or Claim.....	368	—
b. Eliminate “Based Upon” Language and Replace With the Phrase “Dismiss an Action or Claim . . . if Substantially the Same Allegations or Transactions . . . Were Publicly Disclosed”	369	—
c. Retention of News Media as a Trigger to the Public Disclosure Bar.....	375	—
d. One Alternate Element to Satisfy the Original Source Provision Is That the Relator Qualify as a True Whistleblower by Disclosing the Information to the Government Before the Public Disclosure.....	376	—
e. A Second Alternate Element to Satisfy the Original Source Provision Is That the Relator Contribute Valuable Information to the Government That “Materially Adds to the Publicly Disclosed Allegations or Transactions”	377	—
2. Material Revisions to Statute That May Deviate From Existing Precedent	381	3-27
a. No Express Reference to Subsection (e)(4) Divesting a Court of Subject Matter Jurisdiction and DOJ’s Authority to Oppose Dismissal	381	3-27

	<i>Main Volume</i>	<i>Supple- ment</i>
b. Application to Only “Federal” Hearings, Reports, Audits, or Investigations.....	387	—
3. Unresolved Interpretation Questions	387	—
a. What Does It Mean to Be “Publicly” Disclosed?	387	—
b. What Will Be the Impact of the Supreme Court’s Decision in <i>Schindler Elevator</i> ?	388	—
c. Are Disclosures to the Government Public Disclosures?.....	390	—
B. Clarification of Reverse False Claims Provision	393	—
C. Amendments to the FCA’s Whistleblower Retaliation Provision	396	—
D. Amendment Declaring a Claim Paid as a Result of Kickback to Be a False Claim.....	397	—
VI. Conclusion	399	—
Chapter 4 Practical Considerations for Defending Health Care Fraud and Abuse Cases.....	401	4-1
I. The Evolving Nature of Health Care Fraud and Abuse Enforcement.....	404	4-4
A. The Early Days	404	—
B. Medicare and Medicaid	404	—
C. The Late 1970s and 1980s	406	—
D. Deregulation.....	406	—
E. Office of Inspector General	408	—
F. The <i>Hanlester</i> Case.....	409	4-4
G. Modern Trends.....	409	4-4
H. The Patient Protection and Affordable Care Act (ACA)... 1. Accountable Care Organizations	410	—
2. Health Care Fraud and Abuse Investigations	411	—
II. Sources of Health Care Fraud and Abuse Investigations	412	4-5
A. Internal Sources	413	—
B. External Sources	414	—
C. Importance of Determining the Source of Disclosed Information	415	4-5
III. Enforcement and Investigative Agencies	416	4-6
A. Federal Enforcement Agencies.....	416	4-6
B. State Enforcement and Investigative Agencies.....	418	—
C. Private Enforcers [Substitute Text]	419	4-7
IV. Enforcement Weapons	420	4-8
A. Federal Criminal Laws.....	420	4-8
1. General Criminal Laws.....	420	—
2. Health Care–Specific Criminal Statutes	421	4-8
a. Health Insurance Portability and Accountability Act of 1996 (HIPAA).....	421	—
b. Health Information Technology and Clinical Health Act (HITECH)	422	—
c. Patient Protection and Affordable Care Act of 2010 (ACA) and the Federal Anti-Kickback Statute Intent Standard	423	—
B. State Criminal Laws.....	423	—

	<i>Main Volume</i>	<i>Supple- ment</i>
C. Federal Civil Laws	424	4-8
1. The Federal False Claims Act [Substitute Text]	424	4-8
2. Patient Protection and Affordable Care Act of 2010 (ACA) and the FCA	425	4-11
a. Anti-Kickback Violations and the FCA	425	—
b. The Public Disclosure Bar	425	—
c. Report and Return Requirement [Substitute Text]	—	4-11
d. Payment Suspension	427	—
e. Coordination of Integrity Efforts	428	—
D. State Civil Remedies	428	—
E. Federal Administrative Agency Remedies	430	4-14
1. Limited Judicial Review	430	—
2. Suspension of Payments	431	—
3. Revocation of Billing Privileges [New Topic]	—	4-14
F. State Administrative Agency Remedies	432	—
G. Identifying the Remedy Threatened by the Enforcement Agency	433	—
V. Health Care Principles Being Enforced	434	4-15
A. Hierarchy	434	—
B. Importance of Reviewing All the Rules	434	4-15
1. Informal Guidelines	435	—
2. Agency Adjudicative Decisions	436	—
3. Other Pronouncements	437	—
4. Local Coverage Determinations [New Topic]	—	4-15
C. Impact of the Rules	437	—
D. Private Party Interpretations, Practices, and Codes of Conduct	438	—
VI. Government Investigatory Strategies	439	4-15
A. Overview	439	—
B. Enforcement Agency Interviews	440	—
C. Document Production	442	4-15
D. Increase in Investigations of Individuals [New Topic]	—	4-16
VII. Responding to an Investigation	443	—
A. Understanding the Government's Interests	443	—
B. Communicating With Enforcement Agents and Their Attorneys	444	—
C. Explaining the Client's Position	445	—
D. Position Papers	445	—
E. The Context Concept	446	—
F. Explaining Industry Terms and Practices	448	—
VIII. Impact of Investigations	450	—
A. Timing	450	—
B. Publicity	450	—
C. Effect on Business	451	—
D. Cash Flow Consequences	451	—
E. Suing Government Officials for Reckless Investigations and Related Actions	452	—
IX. Settlement Considerations	453	4-17
A. Collateral Consequences	453	4-17

	<i>Main Volume</i>	<i>Supple- ment</i>
B. Binding the Government.....	454	—
C. Settlement Goals.....	455	—
D. Life After a Settlement.....	455	—
E. Settling an FCA Case With a Relator [New Topic]	—	4-17
X. Litigation Defense Strategies.....	456	4-17
A. Importance of the Fundamentals	456	4-17
1. Necessity of Prohibited Act or Omission	456	4-17
2. Necessity of Wrongful Intent	457	4-18
3. Necessity of Agency Authority to Act	460	—
B. Other Practical Defense Concepts	461	—
1. Stressing the Facts	461	—
2. Burden of Proof Requirements.....	461	—
3. Credibility of Defendant.....	462	—
4. Limited Judicial Review	462	—
XI. Current Enforcement Priorities	463	4-19
A. Historic Trends in Health Care Fraud Prosecution	463	4-19
B. Focus Areas for OIG Investigation and Enforcement.....	465	—
C. Noteworthy Settlements Since 2010.....	469	4-20
XII. Enforcement Actions Involving Pharmaceuticals	472	4-22
A. Introduction.....	472	—
B. Enforcement Actions Involving Pricing Methodologies...	473	4-22
1. Price Inflation Through Average Wholesale Price Data.....	473	4-22
2. Medicaid Drug Rebate Program.....	476	—
C. Illegal Marketing.....	478	—
1. Kickbacks	478	—
2. Drug Switching.....	482	—
3. Marketing Off-Label Uses.....	483	—
4. Free Samples	490	—
D. Defense Strategies.....	492	—
1. Federal False Claims Act.....	492	—
a. Government Knowledge of Pricing Scheme	492	—
b. Challenging Scienter	493	—
c. Challenging Causation	495	—
2. Anti-Kickback Statute	496	—
a. Kickbacks as False Claims: Lack of Certification.....	496	—
b. Statutory Exception and Safe Harbor Protection: Discounts and Educational Grants...	497	—
E. Class Action Lawsuits on Behalf of Private Payors and Patients.....	498	—
F. Counterfeit Drugs, Illegal Wholesaling, and Internet Pharmacies	498	—
G. Laws Empowering Enforcement Agencies.....	498	—
H. Conclusion	501	—
XIII. The Intersection of the Stark Law and the False Claims Act.....	501	4-23
A. Introduction.....	501	—
B. Basis for Liability	502	4-23
C. Litigation Involving the Stark Law and the FCA	503	—

	<i>Main Volume</i>	<i>Supple- ment</i>
D. Defense Strategies.....	507	—
E. Conclusion	508	—
XIV. Emerging Issues: Sarbanes-Oxley and the Era of Corporate Responsibility	509	—
A. Relevant Provisions of the Sarbanes-Oxley Act	509	—
B. Litigation.....	510	—
XV. Conclusion	511	—
Chapter 5 Legal Issues Surrounding Hospital and Physician Relationships	513	5-1
I. Background on the Nature of Relationships Between Hospitals and Physicians and the Factors Affecting Those Relationships.....	515	5-4
II. Legal Issues.....	517	5-5
III. Relationships With Physicians Who Are Members of the Voluntary Medical Staff	521	5-7
A. Medical Staff Membership [Substitute Text].....	—	5-7
1. Exclusive Contracts	522	—
2. Economic Credentialing	522	—
a. Anti-Kickback Issues	525	—
b. State Issues	525	—
B. Credential Review and Corrective Action	526	5-7
1. Verification of Credentials and Checking Available Databases.....	526	5-7
2. Physician Malpractice Insurance	527	—
3. Hospital Duty to Deal With Problem Practitioners ...	527	—
C. Corrective Action Under the Medical Staff Bylaws [Substitute Text].....	—	5-8
D. Physician Coverage of the Emergency Room [Renumbered Topic, formerly III.E.; Substitute Text].....	—	5-10
1. Reimbursement [Substitute Text]	535	5-11
2. Corporate Practice of Medicine Prohibitions	538	—
E. Perquisites for Members of the Medical Staff [Renumbered Topic; formerly III.F.]	538	5-14
1. Nonmonetary Compensation [Substitute Text]	—	5-14
2. Medical Staff Incidental Benefits [Substitute Text]...	—	5-15
3. Professional Courtesy	541	5-17
4. Compliance Training [Substitute Text].....	—	5-17
F. Donations of Health Information Technology [Renumbered Topic, formerly III.G.]	542	5-18
1. Community-Wide Health Information Systems Exception.....	542	5-18
2. Electronic Prescribing Exception	544	5-19
3. Electronic Health Records Exception [Substitute Text].....	—	5-19
G. Medicare Prohibition on Unbundling [Renumbered Topic, formerly III.H.; Substitute Text]	—	5-22
H. Physician Use of Hospital Clinic Space [Renumbered Topic, formerly III.I.].....	549	5-25
IV. Contractual Relationships With Physicians	550	5-26

	<i>Main Volume</i>	<i>Supple- ment</i>
A. Generally Applicable Limitations Arising From Tax-Exempt Status Can Be the Basis for Intermediate Sanctions Under the Internal Revenue Code	550	5-26
1. Definition of “Disqualified Persons”	551	5-27
2. Definition of “Reasonable Compensation”	553	—
3. Rebuttable Presumption That a Transaction Is Not an Excess Benefit	554	—
4. Rules for Revenue-Sharing Transactions	554	—
B. Lease of Space [Substitute Text]	—	5-27
1. Clarification of “Fair Rental Value”	558	5-30
C. Timeshare Arrangement [New Topic]	—	5-31
D. Lease of Equipment [Renumbered Topic, formerly IV.C.]	560	5-33
E. Medical Director Agreements [Renumbered Topic, formerly IV.D.; Substitute Text]	—	5-35
F. Employing and Contracting With Physicians for the Provision of Patient Care Services [Renumbered Topic, formerly IV.E.]	565	5-38
1. Federal Compliance Issues [Substitute Text]	—	5-38
2. State Corporate Practice of Medicine Prohibitions [Substitute Text]	—	5-43
3. Medicare and Medicaid Prohibitions on the Reassignment of Revenue [Substitute Text]	—	5-44
G. Hospital-Based Physicians [Renumbered Topic, formerly IV.F.]	573	5-47
1. Exclusivity	573	—
2. Anti-Kickback and Stark Issues	574	—
3. False Claims Issues	574	5-47
H. Discounts on Reference Laboratory Services [Renumbered Topic, formerly IV.G.; Substitute Text]	—	5-47
I. Practice Management Services Furnished by Hospitals to Physicians [Renumbered Topic, formerly IV.H.]	577	5-49
J. Academic Medical Centers [Renumbered Topic, formerly IV.I.;	578	5-49
1. Stark Issues [Substitute Text]	—	5-49
2. Anti-Kickback Issues	581	—
K. Gainsharing [Renumbered Topic, formerly IV.J.]	582	5-51
1. Civil Monetary Penalties (CMP) for Improper Incentive Plans [Revised Topic]	583	5-53
2. Gainsharing Within Managed Care [Substitute Text]	—	5-56
3. Stark Issues	591	5-57
4. Anti-Kickback Issues	593	5-58
5. Tax-Exempt Issues	596	—
L. Physician Recruitment [Renumbered Topic, formerly IV.K.]	597	5-59
1. Tax-Exempt Issues	598	—
2. Anti-Kickback Issues [Substitute Text]	—	5-59
3. Stark Issues	606	5-64

	<i>Main Volume</i>	<i>Supple- ment</i>
M. Physician Retention [Renumbered Topic, formerly IV.L.].....	609	5-67
1. Stark Issues.....	609	—
2. Provision of Malpractice Insurance Assistance.....	610	—
N. NPP Recruitment [New Topic].....	—	5-67
V. Joint Ventures Between Hospitals and Physicians.....	612	5-69
A. Whole Hospital Ventures.....	613	5-69
1. Stark Issues [Substitute Text].....	—	5-69
2. Anti-Kickback Issues [Substitute Text].....	—	5-73
3. Tax-Exempt Issues.....	619	5-75
B. Ambulatory Surgery Centers.....	621	5-76
1. Stark Issues [Substitute Text].....	—	5-76
2. Anti-Kickback Issues.....	623	5-76
C. “Under Arrangements”.....	630	5-76
1. Provider-Based Requirements [Substitute Text].....	—	5-76
2. Anti-Kickback Issues [Substitute Text].....	—	5-78
3. Stark Issues [Substitute Text].....	—	5-79
D. Physician-Hospital Organizations.....	634	5-80
1. Capital Requirements and the Need to Avoid Hospital Subsidization of Physician Members.....	634	5-80
2. Antitrust Issues.....	635	5-80
3. Business of Insurance.....	637	—
E. Service Line Leases.....	637	5-81
1. Stark Issues.....	637	—
2. Anti-Kickback Issues.....	638	—
3. Anti-Markup Issues.....	640	5-81
F. Acquisition of Physician Practices.....	641	5-81
G. Clinical Co-Management.....	644	—
H. Accountable Care Organizations [Substitute Text].....	—	5-81
 Chapter 6 Managed Care Fraud and Abuse: Risk Areas for Government Program Participants [Substitute Text].....	 651	 6-1
I. Government-Funded Managed Care Programs and the Enforcement Environment.....	—	6-3
II. Medicare Managed Care.....	—	6-5
A. Introduction.....	—	6-5
B. Compliance Program Requirements.....	—	6-6
C. Government Review, Monitoring, and Audit.....	—	6-7
1. CMS Audits.....	—	6-7
a. Risk Adjustment and Data Validation (RADV) Audits.....	—	6-10
b. Recovery Audit Contractor (RAC) Audits for RADV.....	—	6-12
c. Independent Auditor.....	—	6-14
2. Provider Directories.....	—	6-14
3. Marketing Guidelines and Oversight.....	—	6-15
4. The OIG Work Plans.....	—	6-17

	<i>Main Volume</i>	<i>Supple- ment</i>
a. Medicare Advantage.....	—	6-18
b. Part D.....	—	6-18
D. Enforcement Actions	—	6-19
1. Claims Processing and Coverage Determinations.....	—	6-20
2. Risk Adjustment	—	6-20
3. Marketing and Anti-Kickback Law Violations.....	—	6-23
E. Potential False Claims Act Liability	—	6-24
1. Brief Overview of False Claims Act Liability	—	6-25
2. Overpayments.....	—	6-26
a. Requirement to Report and Return Overpayments.....	—	6-26
b. Case Law Analyzing Overpayment Return Obligations	—	6-28
3. Potential Liability Related to Medicare Secondary Payor Requirements.....	—	6-29
4. Potential Liability Related to the Submission of Certified Rate, Enrollment, and Encounter Data.....	—	6-30
a. Medicare Advantage Bid Submission	—	6-30
b. Part D.....	—	6-30
F. Anti-Kickback Law and Managed Care Safe Harbors	—	6-31
1. Negotiated Rulemaking	—	6-31
2. Capitated Managed Care Entity Safe Harbor	—	6-32
3. Risk-Sharing Safe Harbor.....	—	6-32
4. Common Elements for Both Capitated Managed Care Entity and Risk-Sharing Safe Harbors.....	—	6-34
a. Health Care Items and Services.....	—	6-34
b. No Swapping or Shifting of Financial Burden...	—	6-34
5. Additional Safe Harbors for FQHCs and Free or Discounted Transportation and Certain Cost-Sharing Waivers	—	6-35
G. Prompt Payment and Denial of Care Compliance Issues.....	—	6-35
1. Prompt Payment	—	6-35
2. Denial of Care.....	—	6-36
III. Medicaid Managed Care	—	6-37
A. Introduction.....	—	6-37
1. Overview.....	—	6-37
2. Medicaid Managed Care.....	—	6-39
3. Medicaid Reform.....	—	6-40
B. Compliance Program Requirements	—	6-41
C. Government Review, Monitoring, and Audit.....	—	6-42
1. Federal Oversight	—	6-42
2. State Oversight	—	6-44
D. Enforcement Actions	—	6-44
1. Cherry Picking.....	—	6-44
2. Inflated Medical Claims Expenses	—	6-45
3. Failure to Provide Mandated Care.....	—	6-47
4. Marketing Violations	—	6-47
5. Overpayments.....	—	6-48
6. Bid Contracting Issues.....	—	6-48

	<i>Main Volume</i>	<i>Supple- ment</i>
7. Other Enforcement Trends	—	6-49
E. Potential False Claims Act and Anti-Kickback Law Liability	—	6-51
F. Prompt Payment and Denial of Care Compliance Issues.....	—	6-52
1. Prompt Payment	—	6-52
2. Denial of Care.....	—	6-54
IV. Federal Employees Health Benefits Program	—	6-56
A. Introduction.....	—	6-56
1. Overview.....	—	6-56
2. Types of Plans.....	—	6-56
3. Contract Financing	—	6-56
B. Government Review, Monitoring, and Audit.....	—	6-57
C. Enforcement Actions	—	6-58
D. Potential False Claims Act and Public Contract Anti-Kickback Act Liability	—	6-59
V. TRICARE	—	6-61
A. Introduction.....	—	6-61
1. Overview of Plan Types.....	—	6-61
2. Administration of TRICARE Plans.....	—	6-61
B. Program Integrity Requirements.....	—	6-61
C. Government Review, Monitoring, and Audit.....	—	6-62
D. Enforcement Actions	—	6-62
E. Potential False Claims Act Liability	—	6-63
VI. Conclusion	—	6-64
Chapter 7 Corporate Compliance Programs.....	717	7-1
I. Introduction.....	721	—
II. Benefits of a Corporate Compliance Program	724	7-6
A. Federal Sentencing Guidelines	724	7-8
1. Probation.....	725	—
2. Reduced Fines	727	7-8
3. Elements of an “Effective” Compliance Program.....	728	—
4. Implication of the Supreme Court’s <i>Booker</i> Decision on Corporate Compliance Programs	731	—
B. HHS Guidelines on Permissive Exclusion.....	733	7-8
C. FDA Guidelines for Recommending <i>Park</i> Doctrine Prosecutions.....	736	7-9
III. Elements of an Effective Compliance Program	737	7-10
A. General Criteria	737	7-10
B. Corporate Integrity Agreements and Deferred Prosecution Agreements	738	7-11
C. Evaluating Compliance Program Effectiveness [New Topic]	—	7-14
IV. Model Corporate Compliance Programs	740	7-18
A. Compliance Program Guidance for Hospitals	741	—
1. Hospital Risk Areas	745	—
a. Submission of Accurate Claims and Information.....	746	—
i. Outpatient Procedure Coding.....	746	—

	<i>Main Volume</i>	<i>Supple- ment</i>
ii. Admissions and Discharges	747	—
iii. Supplemental Payment Considerations	747	—
iv. Use of Information Technology	747	—
b. The Physician Self-Referral Law (Stark Law) and Federal Anti-Kickback Statute.....	748	—
i. Stark Law Compliance.....	748	—
ii. Anti-Kickback Compliance.....	749	—
c. Gainsharing Arrangements	751	—
d. EMTALA.....	751	—
e. Substandard Care.....	751	—
f. Relationships With Federal Health Care Beneficiaries	752	—
g. HIPAA Privacy and Security Rules	753	—
h. Topics of General Interest to Hospitals	753	—
2. Ensuring Compliance Program Effectiveness	753	—
a. Developing a General Code of Conduct.....	753	—
b. Regularly Reviewing Compliance Program Elements	754	—
i. Designating a Compliance Officer and Compliance Committee.....	754	—
ii. Developing Compliance Policies and Procedures	755	—
iii. Developing Open Lines of Communication	755	—
iv. Appropriate Training and Education.....	756	—
v. Internal Monitoring and Auditing	756	—
vi. Responding to Detected Deficiencies	757	—
vii. Enforcing Disciplinary Standards	757	—
B. Compliance Program Guidance for Clinical Laboratories	758	7-18
1. Clinical Laboratory Risk Areas	758	—
a. Medical Necessity	758	—
i. Requisition Form.....	758	—
ii. Notices.....	759	—
iii. Physician Acknowledgements.....	759	—
iv. Advanced Beneficiary Notices.....	759	—
v. Test Utilization Monitoring.....	759	—
b. Billing.....	760	—
i. Selecting CPT or HCPCS Codes.....	760	—
ii. Selecting ICD-9-CM Codes	760	—
iii. Tests Covered by Claims for Reimbursement	760	—
iv. Calculations.....	760	—
v. Reflex Testing	760	—
vi. Reliance on Standing Orders.....	760	—
c. Marketing	761	—
d. Prices Charged to Physicians	761	—
2. Ensuring Compliance Program Effectiveness	761	—
a. Dealing With Employees and Contractors	761	—
b. Audits	762	—

	<i>Main Volume</i>	<i>Supple- ment</i>
c. Investigations.....	762	—
C. Compliance Program Guidance for the Durable Medical Equipment, Prosthetics, Orthotics, and Supply Industry.....	763	—
1. DME Risk Areas.....	763	—
2. Ensuring Compliance Program Effectiveness	765	—
a. Compliance Officer Responsibilities.....	765	—
b. Education and Training	765	—
i. Claim Development and Billing Training ...	766	—
ii. Sales and Marketing Training	766	—
iii. Ongoing Education Responsibilities	766	—
c. Hotline	766	—
d. Auditing and Monitoring.....	766	—
e. Corrective Action.....	767	—
D. Compliance Program Guidance for Third-Party Medical Billing Companies	767	—
1. Billing Company Risk Areas	768	—
2. Reporting Provider Misconduct.....	769	—
E. Compliance Program Guidance for Hospices.....	769	—
1. Hospice Risk Areas.....	769	—
F. Compliance Program Guidance for Nursing Facilities.....	771	7-19
1. OIG Compliance Program Guidance for Nursing Facilities.....	771	—
a. Nursing Facility Risk Areas	771	—
i. Quality of Care.....	771	—
ii. Residents' Rights	772	—
iii. Billing and Cost Reporting.....	772	—
iv. Employee Screening.....	772	—
v. Kickbacks, Inducements, and Self-Referrals	773	—
b. Ensuring Compliance Program Effectiveness ...	774	—
i. Auditing and Monitoring.....	774	—
ii. Disciplinary Guidelines.....	774	—
iii. Corrective Action	774	—
2. OIG Supplemental Compliance Program Guidance for Nursing Facilities	774	—
a. Quality-of-Care Risk Areas	775	—
i. Sufficient Staffing	775	—
ii. Comprehensive Resident Care Plans.....	775	—
iii. Appropriate Use of Psychotropic Medications	776	—
iv. Medication Management	776	—
v. Resident Safety	777	—
b. Submission of Accurate Claims Risk Areas	778	—
i. Proper Reporting of Resident Case-Mix	778	—
ii. Therapy Services	778	—
iii. Screening for Excluded Individuals and Entities.....	779	—
iv. Restorative and Personal Care Services	779	—
c. The Federal Anti-Kickback Statute	780	—

	<i>Main Volume</i>	<i>Supple- ment</i>
i. Free Goods and Services	781	—
ii. Services Contracts	781	—
iii. Discounts	782	—
iv. Hospices	783	—
v. Reserved Bed Arrangements	783	—
d. Other Risk Areas	784	—
i. Physician Self-Referrals	784	—
ii. Anti-Supplementation	784	—
iii. Medicare Part D	785	—
iv. HIPAA Privacy and Security Rules.....	785	—
e. An Ethical Culture	785	—
i. Code of Conduct	785	—
ii. Regular Review of Compliance Program Effectiveness	786	—
iii. Communication to Decisionmakers	786	—
f. Self-Reporting	786	—
3. Affordable Care Act Requirements for Compliance and Ethics Programs	786	7-19
G. Compliance Program Guidance for Medicare Advantage Organizations.....	788	—
1. Compliance Program Guidance for Medicare+ Choice Organizations Offering Coordinated Care Plans	788	—
a. Risk Areas	788	—
2. Regulatory Requirements for an Effective Compliance Program for Medicare Advantage Organizations.....	789	—
3. Medicare Managed Care Manual Chapter 21— Compliance Program Guidelines	790	—
H. Compliance Program Guidance for Individual and Small-Group Physician Practices	790	7-19
1. Risk Areas for Physicians	791	—
2. Other Helpful Resources for All Health Care Organizations.....	792	—
I. Compliance Program Guidance for Home Health Agencies	792	—
1. Home Health Agency Risk Areas	793	—
a. Improper Joint Ventures	793	—
b. Billing for Unallowable Costs of Home Health Coordination.....	793	—
c. Unqualified or Unlicensed Personnel.....	793	—
d. Falsified Plans of Care.....	794	—
e. Improper Patient Solicitation Activities and High-Pressure Marketing	794	—
f. Billing for Services to Patients Who Are Not Truly Homebound	794	—
g. Billing for Visits to Patients Who Do Not Require a Qualifying Service	794	—
h. Duplication of Services	795	—
i. Willing Caregivers.....	795	—

	<i>Main Volume</i>	<i>Supple- ment</i>
J. Compliance Program Guidance for Ambulance Suppliers	795	—
1. Ambulance Risk Areas	795	—
a. Medical Necessity and Upcoding.....	795	—
b. Documentation, Billing, and Reporting	796	—
c. Medicare Part A Payment for Services “Under Arrangements”.....	796	—
d. Medicaid Requirements.....	796	—
e. Arrangements With Patients and Other Providers.....	796	—
f. Additional Risk Areas	796	—
2. Making a Compliance Program Effective	797	—
a. Auditing and Monitoring	797	—
K. Compliance Program Guidance for Pharmaceutical Manufacturers	797	—
1. Compliance Program Guidance for Pharmaceutical Manufacturers	797	—
a. Compliance Program Elements	798	—
b. Risk Areas for Drug (and Device) Companies... ..	799	—
i. Integrity of Data Used to Establish Reimbursement	799	—
ii. Kickback and Other Illegal Remuneration	799	—
iii. Risks Related to Purchasers	800	—
(a) Discounts and Remuneration to Purchasers	800	—
(b) Formularies and Formulary Support Services	802	—
(c) Average Wholesale Price	803	—
iv. Relationships With Physicians and Other Referral Sources	803	—
v. Relationships With Sales Agents.....	806	—
vi. Drug Samples.....	806	—
2. Industry Guidance	806	—
3. Medical School and Academic Medical Center Conflict of Interest Policies	807	—
L. Draft Compliance Program Guidance for NIH Grant Recipients	808	—
1. High-Risk Areas for NIH Grant Recipients.....	808	—
a. Time and Effort Reporting	808	—
b. Proper Allocation of Charges	809	—
c. Reporting Financial Support From Other Sources	809	—
M. Part D Compliance Program Guidelines.....	809	7-20
1. Part D Program to Control Fraud, Waste, and Abuse (2006 Prescription Drug Benefit Manual Chapter 9)	809	—
a. Risk Areas	810	—
i. Part D Plan Sponsors.....	810	—
ii. PBMs.....	811	—

	<i>Main Volume</i>	<i>Supple- ment</i>
iii. Pharmacies	811	—
iv. Prescribers	812	—
v. Wholesalers	812	—
vi. Manufacturers	812	—
vii. Medicare Beneficiaries.....	813	—
2. Regulatory Requirements for an Effective Compliance Program for Part D Plan Sponsors	814	—
3. Part D Compliance Program Guidelines (2012 Prescription Drug Benefit Manual Chapter 9).....	814	7-20
a. Description of Compliance Program Elements	815	7-20
b. Part D Sponsor Accountability and Oversight....	820	—
N. Accountable Care Organization Compliance Plans.....	821	—
O. Medicaid Managed Care Organization Compliance Programs [New Topic]	—	7-20
V. Practical Issues in Developing and Implementing a Compliance Program	822	7-21
A. Selecting a Compliance Officer	822	—
B. Developing a Corporate Compliance Program.....	823	7-21
C. Education and Training.....	824	—
D. Budgeting.....	825	7-22
E. Compliance Hotline	826	—
F. Compliance Helpline	827	—
G. Auditing and Monitoring	827	7-23
1. Attorney-Client Privilege.....	827	—
2. External/Expert Reviews	829	—
3. Expert Findings	829	—
4. Types of Reviews.....	829	—
5. Disclosure Obligations and Repayments.....	829	7-23
H. Compliance Developments at the State Level	832	—
I. Evolving Compliance Program Standards	834	—
VI. Conclusion	834	7-24
 Chapter 8 Potential Liabilities for Directors and Officers of Health Care Organizations	 837	 8-1
I. Introduction.....	839	8-3
II. Responsibilities of Directors and Officers	843	8-10
A. Individual Accountability for Corporate Wrongdoing [New Topic]	—	8-10
1. The Yates Memo [New Topic]	—	8-12
2. The United States Attorneys’ Manual [New Topic]	—	8-12
B. Private Equity [New Topic]	—	8-12
C. Criminal Liability [Renumbered Topic, formerly II.A.]...	843	8-14
1. General Rule [Substitute Text]	—	8-14
2. Responsible-Corporate-Officer Doctrine [Substitute Text].....	—	8-23
D. Civil Liability [Renumbered Topic, formerly II.B.]	856	8-29
1. Fiduciary Responsibilities and Duties	857	8-29
a. Duty of Loyalty	857	—

	<i>Main Volume</i>	<i>Supple- ment</i>
i. Good Faith.....	858	—
ii. Fairness (No Conflicts)	859	—
iii. Usurping Corporate Opportunity	860	—
b. Duty of Care	861	8-29
c. Duty of Candor.....	861	—
d. Duties of Nondirector Officers.....	862	—
e. Other Types of Exposure	863	8-30
2. Limitations on the Liability of Directors and Officers	865	8-31
a. Business Judgment Rule.....	865	8-31
b. Statutory and Corporate Measures to Reduce Directors' and Officers' Liability	868	—
c. Indemnification and Insurance	869	8-32
E. Nonmonetary Measures to Deter Misconduct [Renumbered Topic, New Topic].....	—	8-33
1. Permissive Exclusion [New Topic]	—	8-33
2. Potential Liability for Future Misconduct [New Topic]	—	8-36
F. Impact of Increased FCPA Enforcement on Directors and Officers [Amended Topic; Renumbered Topic, formerly II.D.]	875	8-37
1. FCPA Enforcement in Health Care [New Topic]	—	8-38
2. FCPA Focus on Pharmaceutical Companies [New Topic]	—	8-41
G. Increased Antitrust Scrutiny of the Health Care Industry [Renumbered Topic, formerly II.E.] [Substitute Text].....	879	8-47
H. Impact of Health Care Reform on Health Care Fraud and Abuse Enforcement [Renumbered Topic, formerly II.F.]	883	8-54
I. The Sarbanes-Oxley Act and Related Developments [Renumbered Topic, formerly II.C.]	871	8-57
III. Litigation Against Officers and Directors	887	8-62
A. Shareholder Derivative Actions	887	—
1. Shareholder Derivative Actions in General	887	—
2. Presuit Demand Requirements	888	—
3. Other Requirements for Derivative Actions	890	—
B. Class Actions	890	—
1. Class Action Requirements.....	891	—
2. Class Not Limited to Shareholders.....	892	—
3. The Private Securities Litigation Reform Act and the Securities Litigation Uniform Standards Act.....	893	—
C. The <i>Caremark</i> Decision.....	895	—
1. Background of the Case.....	895	—
2. The Court's Decision	897	—
a. Board's Duty of Care Responsibilities	897	—
b. Appropriate Information Gathering and Reporting Systems.....	899	—
D. The Columbia/HCA Litigation.....	900	8-62

	<i>Main Volume</i>	<i>Supple- ment</i>
1. Columbia/HCA Operations and Government Investigations	901	8-62
2. Shareholders’ Allegations in <i>McCall v. Scott</i>	903	—
3. Defendants’ Response	906	—
4. The Magistrate’s Report and District Court Decision	906	8-63
a. The Test Under Delaware Law	907	—
b. Applying the Test to the Facts in <i>McCall</i>	908	—
i. Improper Actions by Defendants	908	—
ii. The “Red Flag” Theory	908	—
5. The Appellate Court Decisions	910	—
a. The Legal Standards Used	911	—
b. Analysis of the Facts	914	—
c. <i>McCall</i> and the <i>Abbott Laboratories</i> Case	916	—
6. Implications of the Columbia/HCA and <i>Abbott Laboratories</i> Decisions	919	—
a. The Sixth Circuit Decision in <i>McCall</i>	919	—
b. Other Developments Relating to Presuit Demand	922	—
E. <i>Stone v. Ritter</i> —Upholding the <i>Caremark</i> Standard for Director Liability	923	—
F. <i>Spitzer v. Abdelhak</i>	924	—
1. Background of the Case	924	—
2. The Court’s Decision	925	—
IV. Corporate Compliance	927	8-64
A. U.S. Sentencing Guidelines	928	8-64
1. Advantages of Compliance Programs	928	8-64
2. Compliance Programs Must Be “Effective”	929	8-64
3. Concerns Raised by Compliance Programs	937	—
B. Compliance Program Guidance From the Department of Health and Human Services	938	8-65
1. Seven Basic Elements	939	—
2. Specific References to <i>Caremark</i>	940	—
3. Measuring Compliance Program Effectiveness [New Topic]	—	8-65
4. Director and Officer Responsibilities for Compliance [Renumbered Topic, formerly IV.B.3.]	941	8-65
a. Establishing a Compliance Program	941	—
b. Independence of Compliance Functions [New Topic]	—	8-66
c. Continuing Compliance Responsibilities [Renumbered Topic, formerly IV.B.3.b.]	941	8-67
C. SEC/DOJ Guidance on Compliance Programs	943	8-67
D. Additional Guidance for Directors	944	—
V. Recommendations to Reduce Exposure [Substitute Text]	944	8-70
VI. Practical Tips for Private Equity Firms and Portfolio Companies [New Topic]	—	8-76

	<i>Main Volume</i>	<i>Supple- ment</i>
Chapter 9 The Past, Present, and Future of the Anti-Kickback Statute: A Practical History	951	9-1
I. Introduction: That Can't Be Illegal ... Can It?	952	—
A. "The Story You Are About to Hear Is True. The Names Have Been Changed ... "	952	—
B. There's No Business Like the Health Business: A Brief Introduction to the Anti-Kickback Statute	954	—
II. The Anti-Kickback Statute in the Twentieth Century: An Idiosyncratic Chronology of Major Developments	957	9-2
A. A Not-So-Long Time Ago, in a Congress Not So Far Away: A Very Condensed Summary of the Legislative Origins of the Anti-Kickback Statute	957	—
B. A Thin Line: The First "Special Fraud Alerts" and the Expansion of the Kickback Concept in the New Health Care Economy	960	—
C. In a Kickback State of Mind: Judicial Evolution of the Intent Standard.....	965	9-2
D. There Is Safety in Harbors ... Sometimes: The Evolution and Role of the Safe Harbor Regulations (and the Statutory Exceptions).....	975	9-3
E. A Little Friendly Advice: The Rise and Role of OIG Advisory Opinions.....	986	9-7
F. "I'll Take Potpourri for \$200": A Miscellany of Other Sources of OIG Guidance.....	992	9-8
G. An Interim Summation: Key Points to Remember About the Anti-Kickback Statute [Substitute Text]	—	9-9
III. A Brief Sidebar: What's the Difference Between the Stark Law and the Anti-Kickback Statute?	996	—
IV. Assembling the Pieces: A Practical Framework for Anti- Kickback Statute Analysis	1000	—
A. Does the Proposed Arrangement Involve Federal Health Care Program Business?.....	1000	—
1. The Threshold Question: Are There Potential Referrals of Federal Health Care Program Patients Involved?	1000	—
2. But What About "Private-Pay-Only" Deals?.....	1002	—
B. Why Is the Analysis Being Done?	1003	—
C. What Factors Are Relevant to the Analysis (Besides the Law)?	1005	—
D. Does the Arrangement Fit Within (or Come Close to) a Safe Harbor?	1007	—
E. Are There Relevant Advisory Opinions?.....	1010	—
F. Should You Get an Advisory Opinion?.....	1011	—
V. Another Sidebar: The Anti-Kickback Statute and the False Claims Act.....	1012	—
VI. The Anti-Kickback Statute in the Twenty-First Century: The Good, the Bad, and the Highly Uncertain [Substitute Text]	1014	9-12

	<i>Main Volume</i>	<i>Supple- ment</i>
Chapter 10 Controlling Fraud, Waste, and Abuse in the Medicare Part D Program	1019	10-1
I. Introduction [Substitute Text]	—	10-7
II. Compliance Programs for Medicare Part D Plans	1027	10-12
A. Overview of Mandatory Compliance Program.....	1029	—
B. Sponsor Accountability for and Oversight of FDRs.....	1029	—
C. The Elements of an Effective Compliance Program.....	1031	10-13
1. Written Policies and Procedures and Standards of Conduct.....	1031	—
2. Compliance Officer, Compliance Committee, and High-Level Oversight	1031	—
3. Effective Training and Education	1034	10-13
4. Effective Lines of Communication.....	1034	—
5. Well-Publicized Disciplinary Standards	1034	—
6. Effective System for Routine Monitoring, Auditing, and Identification of Compliance Risks [Substitute Text].....	1034	10-13
7. Procedures and System for Prompt Response to Compliance Issues	1036	10-15
III. Part D Regulatory Requirements Aimed at Addressing Significant FWA Risk	1036	10-15
A. Sales and Marketing Practices	1036	10-15
1. Broker and Sales Agent Conduct in Marketing to and Enrolling Beneficiaries [Substitute Text].....	1038	10-16
2. Presenting Accurate Information About Medicare Part D Plans [Substitute Text].....	1041	10-18
3. Other Improper Sales and Marketing Practices [Substitute Text].....	1041	10-19
4. Communications by Pharmacies and Other Providers to Beneficiaries About Medicare Part D Plans [Substitute Text].....	1042	10-21
B. Formulary Development and Maintenance [Substitute Text].....	1043	10-22
C. Data Reporting Requirements.....	1046	10-26
D. Overutilization and Waste [Substitute Text]	1048	10-26
E. Return and Reporting of Overpayments [Substitute Text].....	1051	10-31
F. Coverage Gap Discount Program	1052	10-33
G. Prescription Transfers and Automatic Refills	1053	10-34
H. Preferred Pharmacy Networks [Substitute Text]	1054	10-34
I. Enrollment of Prescribers [New Topic; Substitute Text]	—	10-36
IV. Oversight, Monitoring, and Auditing	1055	10-39
A. Sponsor	1055	—
B. CMS	1056	10-39
1. CMS Audits [Substitute Text].....	1057	10-41
2. Data Analysis and Validation [Substitute Text]	1059	10-46
3. Complaint Monitoring [Substitute Text]	1061	10-48

	<i>Main Volume</i>	<i>Supple- ment</i>
4. The Part D RAC Program [Substitute Text]	1061	10-48
5. Marketing Surveillance.....	1062	10-49
6. Overutilization Monitoring System [New Topic]	—	10-50
7. Sponsor-Funded Independent Compliance Audits [New Topic]	—	10-51
C. OIG	1063	10-52
1. Prior Part D Work Plan Study Results [Revised Topic].....	1064	10-53
a. Implementation of Required Programs to Deter FWA.....	1064	10-53
b. Medicare Drug Plan Sponsors' Identification of Potential Fraud and Abuse	1065	10-53
c. Medicare Prescription Drug Sponsors' Training on FWA.....	1065	10-54
d. Bid Submission by Part D Sponsors	1066	—
e. Medicare Part D Payments on Behalf of Deceased Beneficiaries [Revised Topic; Substitute Text].....	—	10-54
f. Reconciliation Payments for 2006 and 2007.....	1067	—
g. Medicare Drug Integrity Contractors' Detection of Fraud and Abuse	1067	—
h. E-Prescribing in Part D	1068	—
i. Medicare Prescription Drug Plans Formulary Changes	1068	—
j. Beneficiaries Remain Vulnerable to Sales Agents' Marketing of Medicare Advantage Plans	1068	—
k. Invalid Prescriber Identifiers on Medicare Part D Drug Claims	1069	—
l. Medicare Part D—Prescription Drug Event Reconciliation Process	1069	—
m. Reviews of Less-Than-Effective Drugs in the Medicare Part D Program.....	1070	—
n. Concerns With Rebates in the Medicare Part D Program	1071	—
o. Review of Erectile Dysfunction Drugs in the Medicare Part D Program.....	1072	—
p. Review of CMS Audits of Sponsors' Financial Records.....	1072	—
q. Audits of Medicare Prescription Drug Plan Sponsors by CMS.....	1073	10-55
r. Review of Excluded Providers in the Medicare Part D Program.....	1074	—
s. Medicare Atypical Antipsychotic Drug Claims for Elderly Nursing Home Residents and Ensuring That Medicare Part D Reimbursement Is Limited to Drugs Provided for Medically Accepted Indications	1074	—
t. Retail Pharmacies With Questionable Part D Billing.....	1076	—

	<i>Main Volume</i>	<i>Supple- ment</i>
u. Medicare Advantage Organizations’ Identification of Potential Fraud and Abuse.....	1076	10-56
v. Medicare Could Be Paying Twice for Prescription Drugs for Beneficiaries in Hospice Care	1077	10-56
w. Inappropriate Medicare Part D Payments for Schedule II Drugs Billed as Refills	1078	—
x. MEDIC Benefit Integrity Activities in Medicare Parts C and D [Substitute Text].....	—	10-56
y. Gaps in Oversight of Conflicts of Interest in Medicare Prescription Drug Decisions.....	1079	—
z. Impact on Medicare Program of Investment Income That Medicare Part D Plans Earned and Retained From Medicare Funds in 2009 [New Topic].....	—	10-57
aa. Prescribers With Questionable Patterns in Medicare Part D Plans [New Topic].....	—	10-57
bb. Medicare Inappropriately Paid for Drugs Ordered by Individuals Without Prescribing Authority [New Topic]	—	10-58
cc. Medicare Improperly Paid Millions of Dollars for Prescription Drugs Provided to Unlawfully Present Beneficiaries During 2009 Through 2011 [New Topic].....	—	10-59
dd. CMS Should Improve Oversight for the Transfer of True Out-of-Pocket Costs Between Part D Plans [New Topic].....	—	10-59
ee. Medicare Improperly Paid Millions of Dollars for Prescription Drugs Provided to Incarcerated Beneficiaries During 2006 Through 2010 [New Topic]	—	10-60
ff. CMS Regularly Reviews Part C Reporting Requirements Data, but Its Follow-Up and Use of the Data Are Limited [New Topic]	—	10-60
gg. CMS Provided Part D Coverage to Beneficiaries Confined in Mental Health Facilities for Court-Ordered Purposes [New Topic]	—	10-61
hh. Part D Beneficiaries With Questionable Utilization Patterns for HIV Drugs [New Topic]	—	10-62
ii. Use of Copayment Coupons for Part D Drugs [New Topic]	—	10-62
jj. Medicaid Rebates for Brand-Name Drugs Compared to Part D Rebates [New Topic]	—	10-64
kk. High Part D Spending on Opioids and Substantial Growth in Compounded Drugs Raise Concerns [Revised Topic]	—	10-64
2. 2018 Active Work Plan Items [Revised Topic; Substitute Text].....	—	10-65

	<i>Main Volume</i>	<i>Supple- ment</i>
a. Planned Studies and Audits Related to Medicare, Sponsor and Manufacturer Policies and Practices [Revised Topic; Substitute Text].....	—	10-66
i. Savings Potential of Adjusting Risk Corridors [Revised Topic; Substitute Text]	—	—
ii. Medicare Part D Beneficiaries' Exposure to Inappropriate Drug Pairs [New Topic]....	—	—
iii. Review of Financial Interests Reported Under the Open Payments Program [New Topic].....	—	—
iv. Data Brief: Opioid Use in Medicare Part D [New Topic]	—	10-66
b. Planned Studies and Audits Addressing Sponsor Compliance With Part D Requirements [Revised Topic; Substitute Text].....	—	10-66
i. Reconciliation of Payments—Sponsor Reporting of Direct and Indirect Remuneration [Revised Topic; Substitute Text]	—	—
ii. Ensuring Dual Eligibles' Access to Drugs Under Part D [Revised Topic; Substitute Text]	—	10-66
iii. Recommendation Follow-Up—Oversight of Conflicts of Interest in Medicare Prescription Drug Decisions [Revised Topic; Substitute Text]	—	10-66
iv. Medicare Part D Eligibility Verification Transactions [Revised Topic; Substitute Text]	—	10-66
v. Part D Pharmacy Enrollment [Revised Topic; Substitute Text]	—	10-67
vi. Part D Sponsors' Reporting of Direct and Indirect Remunerations [New Topic] ...	—	10-67
vii. Invalid Prescriber Identifiers on Medicare D Drug Claims in 2016 [New Topic].....	—	10-67
c. Planned Studies and Audits Regarding Part D Billing and Payment Issues [Revised Topic].....	—	10-67
i. Medicare Part D Rebates Related to Drugs Dispensed by 340B Pharmacies [Revised Topic; Substitute Text]	—	10-67
ii. Questionable Billing for Compounded Topical Drugs in Part D [Revised Topic; Substitute Text]	—	10-68

	<i>Main Volume</i>	<i>Supple- ment</i>
iii. Medicare Part D Payments for Service Dates After Individuals' Dates of Death [Revised Topic; Substitute Text]	—	10-68
iv. Documentation of Pharmacies' Prescription Drug Event Data [Revised Topic]	—	10-68
v. Quality of Sponsor Data Used in Calculating Coverage Gap Discounts [Revised Topic]	—	10-68
vi. Increase in Prices for Brand-Name Drugs Under Part D [New Topic]	—	10-69
vii. Duplicate Drug Claims for Hospice Beneficiaries [New Topic].....	—	10-69
d. Planned Studies and Audits Related to the Cost of the Part D Program [Revised Topic; Substitute Text].....	—	10-69
i. Risk Sharing and Risk Corridors—Savings Potential of Adjusting Risk Corridors [Substitute Text]	—	—
ii. Program Integrity—Beneficiary Use of Manufacturer Copayment Coupons [Substitute Text]	—	—
iii. Comparison of Medicare Part D and Medicaid Pharmacy Reimbursement and Rebates [Substitute Text]	—	—
iv. Medicare Drug Integrity Contractor's Activities [New Topic]	—	10-69
D. OIG Sponsor Audits.....	1084	10-70
1. OIG Review of SilverScript Internal Controls to Guard Against FWA for the Medicare Part D Program [Substitute Text].....	—	10-70
2. OIG Review of Sterling Life Insurance Company's Internal Controls to Guard Against FWA for the Medicare Part D Program	1085	—
3. OIG Review of Aetna, Inc., Pharmacy Audit Recoveries for Medicare Part D Drugs Dispensed in Calendar Year 2008.....	1086	—
4. OIG Review of Community Insurance, Inc., Prescription Drug Events for Institutionalized Beneficiaries for Calendar Year 2008	1087	10-71
5. OIG Review of United Healthcare of Wisconsin, Inc., Prescription Drug Events for Institutionalized Beneficiaries for Calendar Year 2008	1088	—
6. OIG Review of Part D Prescription Drug Event Data for Schedule II Drugs.....	1088	—
E. Patient Assistance Programs and Other Arrangements: Special Advisory Bulletins and Advisory Opinions [Revised Topic].....	1091	10-72
1. Other Arrangements That Provide Drugs Outside the Part D Benefit [New Topic]	—	10-77

	<i>Main Volume</i>	<i>Supple- ment</i>
V. Enforcement Actions.....	1092	10-80
A. CMS [Substitute Text]	—	10-80
1. Actions Against Sponsors [Revised Topic]	—	10-80
2. Actions Against Pharmaceutical Manufacturers [Revised Topic].....	—	10-96
B. OIG	1100	10-97
C. FTC	1100	—
D. State Insurance Departments	1100	—
E. False Claims Act Cases Related to Medicare Part D [Substitute Text].....	1101	10-98
F. The Future of Part D Regulation and Enforcement in the Trump Administration [New Topic].....	—	10-109
Chapter 11 Fraud and Abuse Issues Surrounding Clinical Trials	1105	11-1
I. Introduction.....	1106	11-2
II. Financial Misconduct in Clinical Research	1107	11-3
A. Payment for Clinical Research	1107	11-3
1. Background and General Description	1107	11-3
a. Medicare Coverage for Clinical Trials and Related Costs.....	1107	11-3
i. National Coverage Determination.....	1107	—
ii. Device Trials	1109	11-3
b. General Parameters for Billing Third-Party Payers for Experimental Treatment.....	1110	—
c. Payments for Treatment of Research-Related Injuries: Medicare Secondary Payer Rule	1110	11-5
2. Fraud and Abuse Risks Associated With Payment for Clinical Trials and Related Costs.....	1112	11-6
a. False Claims Act Violations	1112	11-6
b. Anti-Kickback Statute Violations.....	1114	11-6
c. Stark Law Violations	1118	11-8
d. Beneficiary Anti-Inducement Statute Violations.....	1119	—
e. Exclusion.....	1120	—
f. Foreign Corrupt Practices Act Violations.....	1121	11-8
3. Recommendations for Compliance	1124	—
a. Pretrial Budget Evaluation and Preparation	1124	—
b. Research Billing Procedures	1124	—
c. Audits	1125	—
d. Development and Updating of Policies, Procedures, and Training	1125	—
B. Federal Grants Management	1125	11-9
1. Background and General Description	1125	11-9
a. Certifications	1126	11-9
b. Time-and-Effort Reporting and Salary Allocation [Substitute Text]	—	11-10
c. Allowable Costs [Substitute Text].....	—	11-11
d. Cost Transfers.....	1130	11-12

	<i>Main Volume</i>	<i>Supple- ment</i>
e. Subrecipient Monitoring [Substitute Text].....	—	11-12
2. Fraud and Abuse Risks Associated With Mismanagement of Federal Grant Funds	1132	11-13
a. False Claims Act Violations	1132	11-13
b. Exclusion	1134	—
3. Recommendations for Compliance	1135	—
III. Misconduct in Protecting Human Subjects.....	1136	11-14
A. Overview of Human Subject Protection Regulations	1137	11-14
1. General Human Subject Protection [Substitute Text].....	—	11-14
a. Informed Consent Requirements [Substitute Text]	—	11-15
b. IRB Requirements	1138	—
2. Conflicts of Interest	1139	11-16
B. Fraudulent Activities by Researchers	1142	11-18
1. Informed Consent.....	1142	11-18
2. Conflicts of Interest.....	1142	—
3. Misrepresentation to IRBs.....	1143	—
4. Misrepresentation to Regulatory Agencies.....	1143	11-19
C. Recommendations for Compliance.....	1145	—
IV. Research Misconduct.....	1146	—
A. Description of Research Misconduct and Associated Fraud and Abuse Risks	1146	—
B. Recommendations for Compliance.....	1150	—
V. Conclusion	1150	—
Appendices	1151	App-1
Appendix A: Anti-Kickback Statute Materials	—	App-1
Appendix B: Stark Self-Referral Law Materials.....	—	App-2
Appendix C: Civil False Claims Act Materials.....	—	App-4
Appendix D: Civil Monetary Penalties and Exclusion Materials	—	App-5
Appendix E: Selected Health Care Fraud Statutes Related to Private Payer Fraud.....	—	App-6
Appendix F: Special Fraud Alerts and Advisory Bulletins.....	—	App-6
Appendix G: Advisory Opinion Materials: Anti-Kickback Statute and Stark Self-Referral Law	—	App-9
Appendix H: Office of Inspector General Self-Disclosure Protocol.....	—	App-10

Detailed Table of Contents

lvii

	<i>Main Volume</i>	<i>Supple- ment</i>
Appendix I: Office of Inspector General Compliance Materials and Related Industry Documents	—	App-10
Appendix J: Medicare and Medicaid Managed Care Materials	—	App-11
Appendix K: Electronic Technology Materials.....	—	App-13
Appendix L: ACA Materials.....	—	App-14
Table of Cases	1157	T-1
Index	1175	—

